PE20020221A1 - CARBAMATOS AZABICICLICOS COMO AGONISTAS DEL RECEPTOR DE ACETILCOLINA NICOTINICO alfa 7 - Google Patents

CARBAMATOS AZABICICLICOS COMO AGONISTAS DEL RECEPTOR DE ACETILCOLINA NICOTINICO alfa 7

Info

Publication number
PE20020221A1
PE20020221A1 PE2001000399A PE2001000399A PE20020221A1 PE 20020221 A1 PE20020221 A1 PE 20020221A1 PE 2001000399 A PE2001000399 A PE 2001000399A PE 2001000399 A PE2001000399 A PE 2001000399A PE 20020221 A1 PE20020221 A1 PE 20020221A1
Authority
PE
Peru
Prior art keywords
nicotinum
agonists
receptor
alpha
azabycyclic
Prior art date
Application number
PE2001000399A
Other languages
English (en)
Spanish (es)
Inventor
Joachim Nozulak
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20020221A1 publication Critical patent/PE20020221A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PE2001000399A 2000-05-05 2001-05-03 CARBAMATOS AZABICICLICOS COMO AGONISTAS DEL RECEPTOR DE ACETILCOLINA NICOTINICO alfa 7 PE20020221A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0010955.3A GB0010955D0 (en) 2000-05-05 2000-05-05 Organic compounds

Publications (1)

Publication Number Publication Date
PE20020221A1 true PE20020221A1 (es) 2002-04-23

Family

ID=9891092

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000399A PE20020221A1 (es) 2000-05-05 2001-05-03 CARBAMATOS AZABICICLICOS COMO AGONISTAS DEL RECEPTOR DE ACETILCOLINA NICOTINICO alfa 7

Country Status (29)

Country Link
US (1) US6780861B2 (xx)
EP (1) EP1282620B1 (xx)
JP (1) JP4898062B2 (xx)
KR (1) KR20020093974A (xx)
CN (1) CN1167703C (xx)
AR (1) AR028073A1 (xx)
AT (1) ATE263167T1 (xx)
AU (2) AU2001262257B2 (xx)
BR (1) BR0110521A (xx)
CA (1) CA2407972C (xx)
CZ (1) CZ20023622A3 (xx)
DE (1) DE60102581T2 (xx)
DK (1) DK1282620T3 (xx)
ES (1) ES2218418T3 (xx)
GB (1) GB0010955D0 (xx)
HK (1) HK1054223B (xx)
HU (1) HUP0301866A2 (xx)
IL (1) IL152417A0 (xx)
MX (1) MXPA02010892A (xx)
NO (1) NO20025280D0 (xx)
NZ (1) NZ522226A (xx)
PE (1) PE20020221A1 (xx)
PL (1) PL357435A1 (xx)
PT (1) PT1282620E (xx)
RU (1) RU2002131886A (xx)
SK (1) SK15612002A3 (xx)
TR (1) TR200401007T4 (xx)
WO (1) WO2001085727A1 (xx)
ZA (1) ZA200208969B (xx)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6262265A (ja) * 1985-09-13 1987-03-18 Hitachi Ltd 復水器自動検査補修システム
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
CA2464685A1 (en) * 2001-11-02 2003-05-15 G.D. Searle Llc Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
MXPA04007936A (es) * 2002-02-15 2004-11-26 Upjohn Co Compuestos de aril-sustituidos para el tratamiento de enfermedades.
EP1476448A2 (en) 2002-02-19 2004-11-17 PHARMACIA & UPJOHN COMPANY Azabicyclic compounds for the treatment of disease
DE10234424A1 (de) * 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
EE05516B1 (et) * 2002-09-25 2012-02-15 Memory@Pharmaceuticals@Corporation Indasoolid bensotiasoolid ja bensoisotiasoolid nende valmistamine ning kasutamine
CA2507502C (en) 2002-12-06 2011-11-29 North Shore-Long Island Jewish Research Institute Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
JP2006521345A (ja) * 2003-03-28 2006-09-21 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ニコチン性アセチルコリン受容体の正のアロステリック調節剤
ES2295973T3 (es) * 2003-12-22 2008-04-16 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-bencisoxazoles, y 1,2-bencisotiazoles, y preparacion y usos de los mismos.
US20050170360A1 (en) * 2004-01-30 2005-08-04 Papke Roger L. Variant neuronal nicotinic alpha-7 receptor and methods of use
ATE437880T1 (de) * 2004-02-04 2009-08-15 Neurosearch As Dimere azacyclische verbindungen und deren verwendung
EP1735306A2 (en) 2004-03-25 2006-12-27 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
DE602005024677D1 (de) * 2004-04-22 2010-12-23 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzisoxazole, 1,2-benzoisothiazole, deren herstellung und verwendungen
BRPI0510212A (pt) * 2004-05-07 2007-10-16 Memory Pharm Corp 1h-indazóis, benzotiazóis, 1,2 - benzoisoxazóis, 1,2-benzoisotiazóis, e cromonas e a preparação e usos dos mesmos
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
RU2418797C2 (ru) 2004-12-22 2011-05-20 Мемори Фармасьютиклз Корпорейшн Лиганды никотинового рецептора альфа-7, их получение и применение
US8106066B2 (en) * 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
ES2396300T3 (es) 2008-11-19 2013-02-20 Envivo Pharmaceuticals, Inc. Tratamiento de trastornos cognitivos con (R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
CN102802620A (zh) * 2009-05-11 2012-11-28 英维沃医药有限公司 使用某种α-7烟酸受体与乙酰胆碱酯酶抑制剂结合治疗认知障碍
JP2012533601A (ja) * 2009-07-23 2012-12-27 ノバルティス アーゲー 運動失調症の処置または予防のための、アザビシクロアルキル誘導体またはピロリジン−2−オン誘導体の使用
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α7活化劑之用途
JP5633405B2 (ja) * 2010-02-18 2014-12-03 Jsr株式会社 新規化合物、感放射線性組成物及び硬化膜
WO2011119310A1 (en) * 2010-03-26 2011-09-29 Corning Incorporated Low nonlinearity long haul optical transmission system
WO2011146511A1 (en) 2010-05-17 2011-11-24 Envivo Pharmaceuticals, Inc. A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
WO2012015749A1 (en) 2010-07-26 2012-02-02 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors
EP2667862A1 (en) 2011-01-27 2013-12-04 Novartis AG Use of nicotinic acetylcholine receptor alpha 7 activators
AU2012232711B2 (en) * 2011-03-18 2016-04-28 Novartis Ag Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease
TWI546301B (zh) * 2011-03-18 2016-08-21 健臻公司 葡萄糖神經醯胺合成酶抑制劑
CA2834467A1 (en) * 2011-04-29 2012-11-01 Chiesi Farmaceutici S.P.A. Alkaloid ester and carbamate derivatives and medicinal compositions thereof
MX2014004621A (es) 2011-10-20 2014-08-22 Novartis Ag Biomarcadores predictivos de la capacidad de respuesta al receptor de acetil-colina nicotinico alfa-7.
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
EP2931315B1 (en) 2012-12-11 2017-11-29 Novartis AG Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
ES2883232T3 (es) 2013-01-15 2021-12-07 Novartis Ag Uso de agonistas del receptor nicotínico de acetilcolina alfa 7
EP2945626B1 (en) * 2013-01-15 2018-09-12 Novartis AG Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
US20150313884A1 (en) 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
CN105246485B (zh) * 2013-01-15 2019-03-15 诺华有限公司 α7烟碱型乙酰胆碱受体激动剂的应用
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
EP4185267A1 (en) 2020-07-24 2023-05-31 Genzyme Corporation Pharmaceutical compositions comprising venglustat

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99537A (en) 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical preparations containing them
AU7545894A (en) * 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
WO1996008468A1 (en) 1994-09-14 1996-03-21 H. Lundbeck A/S Carbamoyloxy amine compounds
GB9525261D0 (en) 1995-12-11 1996-02-07 Bayer Ag Carbamic acid derivatives
GB9526560D0 (en) * 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
EP0912563B1 (en) * 1996-06-05 2004-02-18 Lindner, Wolfgang, Prof. Dr. Cinchonan based chiral selectors for separation of stereoisomers
US6525065B1 (en) * 1997-06-30 2003-02-25 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6624173B1 (en) * 1997-06-30 2003-09-23 Targacept, Inc. Pharmaceutical compositions for treating and/or preventing CNS disorders
US5988429A (en) * 1997-10-14 1999-11-23 Pharmadesign, Inc. Blister pack pill dispenser
DE60024651T2 (de) * 1999-09-28 2006-09-28 Eisai Co., Ltd. Chinuclidin-verbindungen und medikamente die diese als aktive wirkstoffe enthalten
US6479510B2 (en) * 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
GB0109871D0 (en) * 2001-04-20 2001-06-13 Glaxo Group Ltd Metering method for particulate material

Also Published As

Publication number Publication date
US6780861B2 (en) 2004-08-24
HUP0301866A2 (hu) 2003-09-29
DE60102581D1 (de) 2004-05-06
NO20025280L (no) 2002-11-04
JP4898062B2 (ja) 2012-03-14
ATE263167T1 (de) 2004-04-15
AU2001262257B2 (en) 2004-11-04
CA2407972C (en) 2010-03-09
KR20020093974A (ko) 2002-12-16
CN1427840A (zh) 2003-07-02
HK1054223A1 (en) 2003-11-21
CZ20023622A3 (cs) 2003-02-12
SK15612002A3 (sk) 2003-04-01
AR028073A1 (es) 2003-04-23
GB0010955D0 (en) 2000-06-28
BR0110521A (pt) 2003-04-08
ES2218418T3 (es) 2004-11-16
PL357435A1 (en) 2004-07-26
DE60102581T2 (de) 2005-02-03
JP2003532731A (ja) 2003-11-05
EP1282620B1 (en) 2004-03-31
EP1282620A1 (en) 2003-02-12
ZA200208969B (en) 2003-10-07
PT1282620E (pt) 2004-07-30
CA2407972A1 (en) 2001-11-15
NZ522226A (en) 2004-08-27
RU2002131886A (ru) 2004-04-10
WO2001085727A1 (en) 2001-11-15
MXPA02010892A (es) 2003-03-27
US20030166654A1 (en) 2003-09-04
AU6225701A (en) 2001-11-20
HK1054223B (zh) 2005-03-04
TR200401007T4 (tr) 2004-07-21
IL152417A0 (en) 2003-05-29
DK1282620T3 (da) 2004-07-19
NO20025280D0 (no) 2002-11-04
CN1167703C (zh) 2004-09-22

Similar Documents

Publication Publication Date Title
PE20020221A1 (es) CARBAMATOS AZABICICLICOS COMO AGONISTAS DEL RECEPTOR DE ACETILCOLINA NICOTINICO alfa 7
RU2007108861A (ru) Трифтометилзамещенные бензамиды в качестве ингибиторов киназ
SE0104334D0 (sv) Therapeutic agents
AR031248A1 (es) Compuestos de ditosilato de quinazolina, composicion farmaceutica, metodo de tratamiento y uso en terapia y proceso para la preparacion de dichos compuestos
AR017182A1 (es) Compuestos de aminotiazol, inhibidores de las kinasas dependientes de ciclinas y las composiciones farmaceuticas que los contienen.
PE20212302A1 (es) Inhibidores de apol1 y sus metodos de uso
AR043187A1 (es) Derivados de piperidina-bencensulfonamida, medicamentos que los contienen y usos para el tratamiento de trastornos del snc.
EA200100798A1 (ru) Пиперидиновые, тетрагидропиридиновые и пиперазиновые производные, их получение и использование
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
SE9702564D0 (sv) New compounds
AR029821A1 (es) Decahidro-isoquinolinas, un proceso para su preparacion, composiciones farmaceuticas que las comprenden y el uso de las mismas para la fabricacion de un medicamento
UY28450A1 (es) Compuestos heteroarilo de 6 miembros para el tratamiento de trastornos neurodegenerativos.
AR041297A1 (es) Derivados de 4-pirrolidino- fenil- bencil eter
UY27593A1 (es) Nuevos compuestos
UY25143A1 (es) Procedimiento para la preparacion de inhibidores de proteasas.
NZ528997A (en) Sulfonamides
PE20040911A1 (es) Derivados de 3h-quinazolin-4-ona como inhibidores selectivos de la monoaminooxidasa b
PE20040267A1 (es) Tiopirimidinas e isotiazolpirimidinas inhibidoras de quinasas
AR034585A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
ES2109953T3 (es) 1,2,3,4-tetrahidrociclopent(b)indoles, 1,2,3,3a,4,8a-hexahidrociclopent(b)indoles sustituidos y compuestos relacionados, compuestos intermedios y un procedimiento para su preparacion y su uso como medicamentos.
SE9702563D0 (sv) Compounds
PE20091187A1 (es) Compuestos derivados de quinolina como moduladores del receptor de serotonina 5-ht6
KR910004559A (ko) 중추 신경계에 작용하는 무스카린성 약제인 4-(n-치환 아미노)-2-부티닐-1-우레아 및 티오우레아와 그의 유도체
PE20030751A1 (es) Benzotiazoles como ligandos del receptor a2a de adenosina
AR050193A1 (es) Derivados de benciloxi-oxopirrolidina como inhibidores de la mao; metodos para su preparacion y medicamentos para el tratamiento de enfermedades neurodegenerativas que los contienen.

Legal Events

Date Code Title Description
FC Refusal